Premutation carriers can present with reduced intelligence quotient (IQ), especially with a deficit of FMR1 protein (FMRP), and can also show a wide spectrum of clinical involvement including medical, neurological, immunological and psychiatric issues. In addition, there are also disorders associated with the premutation such as fragile X-associated primary ovarian insufficiency (FXPOI), which occurs in approximately 20% of premutation females, and fragile X-associated tremor/ataxia syndrome (FXTAS), which occurs in approximately 40% of males and 8-16% of premutation females [reviewed in (1) ].
It is rare for a female to have a premutation on both of her X chromosomes, but this can occur when both the parents carry a premutation allele themselves. This rarity is referred to as a compound heterozygous premutation if the alleles have different numbers of CGG repeats. The probability of having a daughter with a compound heterozygous premutation increases when the parents have a consanguineous relationship.
In a previously reported study, two of three sisters with compound heterozygous premutations, who were offspring from a consanguineous union, developed FXPOI (2) . Another study reported that three compound heterozygous premutation sisters (non-consanguineous) did not have deficits in verbal performance, executive functions, or visual spatial domains by neuropsychological profiles (3) . Another study compared a female with a compound heterozygous premutation to her premutation brother, and reported that while both individuals were of similar ages and CGG repeat sizes, they presented with different cognitive and behavioral profiles with the brother being more affected than his sister (4). To our knowledge, there are only seven compound heterozygous females described in the literature. Here, we present a family with two additional cases. We describe in detail the molecular and psychological evaluation of the two female siblings with the compound heterozygous FMR1 premutation and their family.
Methods
The family was recruited through the fragile X treatment and Research Center at the UC Davis MIND Institute upon approval by the IRB at UC Davis, CA, USA.
Cognitive and molecular testing protocols were as previously described (4) (5) (6) (7) .
Structural magnetic resonance images (MRI) were performed on cases II-1, II-5, I-1, I-2 using a 3.0T Siemens scanner (Siemens Medical Solutions) with Echo speed gradients and a Siemens 8-channel whole head coil (Siemens Medical Solutions, Erlangen, Germany).
Results

Family history
The cases I-1 and I-2 are from a small geographically isolated village in Mexico, which is known to have ID in several members of this community. Although consanguinity is not shown in Fig. 1 , the mother and father of case I-2 were second cousins. Numerous other extended family members have reported intellectual disability (ID), most likely Fragile X syndrome (FXS).
The participant is a 40-year-old compound heterozygous premutation female with 93 and 128 CGG repeats and 2 AGG interruptions on each of her alleles. Her FMR1 mRNA levels were fivefold higher than normal (Table 1) . She achieved developmental milestones at appropriate ages. She has a history of anxiety, panic attacks, and depression. She attempted suicide at 30 years of age. She reported menarche at 13 years of age and has irregular menstrual cycles with severe abdominal cramps. She has chronic shoulder pain and migraine headaches. She reported memory problems for the past 3 years. Her medications included duloxetine, naproxen and bupropion. She has a long narrow face, prominent ears and left shoulder tenderness. Her MRI did not show any atypical findings (Fig. 2a) .
On the Wechsler Adult Intelligence Scale (WAIS-IV), this individual received standard scores of 107 on verbal comprehension, 98 on perceptual reasoning, 83 on working memory, 102 on processing speed, and a full Scale IQ Score of 98. On the Wechsler Memory Scale (WMS-IV), the participant scored 102 in auditory memory, 100 in visual memory, 97 in visual working memory, 103 in immediate memory, and 100 in delayed memory. The participant had a total score 30 on the Mini Mental Status Exam (MMSE), within the normal range. She scored 20 out of possible 27 points on the Behavioral Dyscontrol Scale (BDS-2), which is the low range of normal. On the Structured Clinical Interview for DSM Disorders (SCID-I), she met criteria for past recurrent major depressive disorder in partial remission, past substance abuse disorder (due to alcohol consumption), past panic disorder without agoraphobia, past specific phobia of flying, current generalized anxiety disorder, and pain disorder. On the Symptom Checklist-90-Revised (SCL-90-R), she scored in the clinically significant range for selfreported obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, and paranoia. The Attention Quotient (104) and Response Control Score (100) of the IVA were in the average range. Although she does not show significant neuropsychological deficits, she does have significant emotional difficulties with a suicide attempt in the past in addition to chronic pain and migraine headaches; so she is on the severe end of the spectrum for premutation involvement.
This participant has four children from two different marriages. Case II-1 verbally reported that cases III-2, III-3, and III-4 have FXS, whereas case III-1 has behavioral problems including shyness and perfectionistic features.
The patient is a 38-year-old compound heterozygous fragile X premutation carrier with 89 and 110 CGG repeats (Fig. 2) . She has two AGG interruptions on each of her alleles. Her FMR1 mRNA level is fourfold higher than normal (Table 1) . She reported menarche at 15 years and had her last menstrual period at the age of 27, indicative of FXPOI. She has a history of dizziness, orthostatic hypotension, sleep disturbances, insomnia, migraine headaches, and anxiety. She also has obsessive-compulsive features, including excessive cleaning. She has a long face with prominent ear lobes, a mildly high arched palate, alternating exotropia, hypermobility of joints and flat feet.
On the WAIS-III, the verbal IQ was 106 (average), performance IQ of 122 (superior), and full Scale IQ of 113 (average). On the WMS-III, the participant scored 99 on auditory memory, 100 in visual memory, 99 in visual working memory, 100 in immediate memory, and 107 in general memory. She scored 21 points on the BDS-2. The response control quotient in the IVA fell in the average range (105), her attention quotient is at low average range (84), with a borderline score in visual attention. The SCL-90-R showed clinically significant traits for self-reported obsessive-compulsive symptoms, anxiety, hostility, and phobia. On the Beck Anxiety Inventory (8), she selfreports significant anxiety symptoms. On the SCID, she met criteria for generalized anxiety disorder and panic disorder with agoraphobia/social phobia. She also met criteria for major depression and dysthymia. Her brain MRI was read as normal (Fig. 2b) . Overall, she does not show neuropsychological deficits but her emotional and neurological problems including dizziness and orthostatic hypotension in addition to connective tissue problems are more significant than what is seen in the majority of premutation carriers at age 38.
This individual is a 69-year-old male with 183 CGG repeats (Fig. 2) containing two AGG interruptions. His FMR1 mRNA levels were sixfold higher than in normal individuals ( Table 1) . As a child, he reached developmental milestones at appropriate ages. He has had depression and anxiety for the past 10 years. He has intermittent episodes of dizziness and swallowing problems, remarkable with liquids. His past medical history is remarkable for stroke without complications, at the age of 60. He does not have a history of dislocation or chronic pain, but reported to have an inguinal hernia. He takes fluoxetine, atorvastatin and escitalopram oxalate. His physical examination did not show ataxia or tremors. He has a long face, large ears (>7 cm) and normal testicular size. IQ testing showed verbal and performance abilities within the normal range (Table 1) . On the SCL-90-R, he scored in the borderline clinically significant range for self-reported obsessive-compulsive symptoms, depression, anxiety, phobia, paranoia, and psychoticism. His structural brain MRI showed mild cerebral atrophy involving frontal and parietal regions and some hyperintensities in the white matter regions of the prefrontal lobe (Fig. 2c) .
This participant is a 69-year-old female born to parents who were second cousins. She has 29 and 76 CGG repeats and an activation ratio of 0.32 (Fig. 2) . She has two AGG interruptions on each allele. FMR1 mRNA levels were within the normal range (Table 1) . She reported as a child she was shy and had tantrums. She has daily anxiety symptoms, moderate depression for the past 2 years and sleep disturbances for the past 10 years. She usually sleeps 4-5 h a day. She reported memory problems for the past 2 years. She reported menarche at the age of 15 and had a hysterectomy at the age of 32 for a non-specified cause. She also has osteoporosis and hypercholesterolemia. Her physical exam was unremarkable, although she has long face and large ears (>7 cm). She had no ataxia or tremor. On the WAIS-III, the full Scale IQ was in the low average range (82). The MMSE Score of 28 does not show any impairment in orientation or cognitive status. The BDS-2 Score of 11 fell in the moderately impaired range and points to problems with executive functioning. On the SCL-90-R, she scored in the clinically significant range for self-reported somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, phobia, and psychoticism. Her structural brain MRI showed mild atrophy in the prefrontal cortex and cerebellum.
Discussion
Consanguinity and inbreeding increases the risk for X-linked syndromes in females, which in many recessive disorders results in affected females. Cases I-1 and I-2 are from a small and isolated village with a high incidence of ID which explains the presence of compound heterozygous premutation in two members of this family. The FMR1 premutation is the most common genetic cause of fragile X-associated primary ovarian insufficiency (FXPOI) defined as cessation of menses before age 40 and has an incidence of about 20% in female carriers (9) . The pathophysiology is unclear; however, FMRP in early development (before the X inactivation) may play a role in proliferation of oocytes and later in life, the accumulation of FMR1 mRNA can lead to follicular atresia. Case II-5 experienced symptoms consistent with FXPOI at the age of 27 while case II-1 did not experience these symptoms even though case II-1 had higher expression of FMR1 mRNA levels. FXPOI is characteristic of females with the premutation and is not reported to have a higher incidence in compound heterozygous premutation females; however, the number of cases reported is too small to make any conclusions.
Cases I-1 and II-5 scored within the normal range for intelligence and memory, which is consistent with previously reported compound premutation females (2, 3); however, the BDS-2 results showed a comparable low score in executive functioning for both individuals and this is consistent with previous reports of executive function deficits or attention deficit hyperactivity disorder (ADHD) symptoms in carriers (10) .
Depression and anxiety are the most common psychiatric problems of adults with the premutation and normal intellectual abilities (11) . The psychiatric interview (SCID-I) showed a similar profile for both individuals, emphasizing an increased rate of depression and anxiety. Cases I-1, I-2, II-1, and II-5 presented with similar severity of anxiety and depression. Interestingly, the onset of these symptoms was described earlier in the compound heterozygous premutation females (early 20s) than the parents with the premutation (40s). Sisters did not appear to show additive cognitive effects, but the psychiatric problems were worse than typically seen in carriers and they started earlier in life so the compound premutation may have influenced the age of presentation and severity of their psychiatric problems. Cases I-1, I-2, II-1, and II-5 reported chronic migraines which are commonly seen in about 50% of patients with a premutation and they are often difficult to treat (12) .
Neurological problems are common in aging premutation carriers including neuropathy, tremor, ataxia and cognitive decline, which are the symptoms of FXTAS (1). Cases I-1 and I-2 did not present typical symptoms of FXTAS. This is particularly remarkable for case I-1, because his FMR1 mRNA expression levels were elevated (Table 1) , which puts him at high risk for FXTAS. It is possible he has been protected by a gene modifier, the lack of environmental toxicity, and his healthy lifestyle. He has a healthy diet, exercises regularly and does not smoke or drink alcohol. The 183 CGG repeats allele decreased during transmission to his two daughters (Cases II-1 and II-5); contraction has been commonly observed during paternal transmission (13) . The maternal transmission remained stable, which is most likely due to the presence of two AGG anchors in agreement with the predicted risk model (7) .
In conclusion, we report on an interesting family with two compound heterozygous premutation females with similar molecular results, but vary in severity of medical symptoms and psychopathological involvement. MRI results show that both cases I-1 and I-2 do not present any FXTAS-specific findings, which suggest of a protective factor in this family.
